Summary

Market Size & Trends

The Japan next-generation sequencing market size was valued at USD 387.5 million in 2024 and is projected to grow at a CAGR of 17.24% from 2024 to 2033. Key drivers of this growth include the declining costs associated with genetic sequencing and significant advancements in cloud computing and data integration technologies. Moreover, rising investments in cancer treatment and the broad application of next-generation sequencing (NGS) in cancer diagnosis and therapy are expected to propel market expansion further.

Rising Cancer Burden & Precision Medicine Initiatives

Japan faces some of the highest cancer rates and death rates worldwide, which continue to put a lot of pressure on its healthcare system. This increasing burden creates a strong need for advanced diagnostic tools that allow early detection, accurate characterizations of tumors, and improved treatment choices. Next-generation sequencing (NGS) has become a key technology in this effort, as it enables detailed genomic profiling of tumors, identification of actionable mutations, and monitoring of disease progression through liquid biopsies. The clinical usefulness of NGS in oncology is gaining recognition across Japan’s hospitals and cancer research centers, leading to broader adoption in routine cancer diagnostics.

Government-backed precision medicine initiatives further accelerate this trend by promoting the integration of NGS into mainstream clinical practice. National programs like the Cancer Genomic Medicine Program, established by Japan’s Ministry of Health, Labour and Welfare, have appointed specialized cancer genome medical centers across the country, ensuring equitable access to advanced sequencing-based diagnostics. Additionally, companion diagnostics for targeted therapies are increasingly gaining approval from Japan’s regulatory authorities, which boosts the clinical demand for NGS technologies. Since oncology remains the largest application area for NGS in Japan, the combined effect of rising cancer rates and supportive government precision medicine efforts is a strong driver of market growth.

Supportive Government Policies & Genomic Programs

The Japanese government has played a key role in increasing the use of next-generation sequencing (NGS) technologies by creating a supportive research and regulatory environment. National initiatives like the Japan Genomic Medicine Program and the Cancer Genomic Medicine Promotion Plan have allocated significant funding for large-scale genomic research, including population-based genome sequencing projects and clinical cancer genome studies. These programs aim to boost academic research and develop strong databases that form the basis for translational medicine, biomarker discovery, and new therapeutic development. By investing in infrastructure such as cancer genome sequencing centers and national biobanks, Japan enables researchers to access high-quality genomic data that speed up discoveries in disease mechanisms and personalized treatments.

The country’s regulatory framework has progressed to support faster and smoother integration of NGS into research and clinical workflows. The Pharmaceuticals and Medical Devices Agency (PMDA) has established clear approval pathways for NGS-based diagnostic panels and companion diagnostics, lowering barriers for academic groups and industry researchers to develop new assays and platforms. These supportive policies foster collaborations among universities, hospitals, and biotechnology companies, creating a thriving research ecosystem. The alignment of government funding, regulatory support, and institutional participation makes Japan one of the most research-intensive markets for NGS worldwide, establishing it as a hub for genomics-driven innovation in Asia.

Japan Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the Japan next generation sequencing market on the basis of technology, product, end use, workflow, and application:

• Technology Outlook (Revenue in USD Million, 2021 - 2033)
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
o DNA-based
o RNA-based
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
o Sample Preparation
o Target Enrichment
• Platforms
o Sequencing
o Data Analysis
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
o Diagnostics and Screening
o Oncology Screening
o Sporadic Cancer
o Inherited Cancer
o Companion Diagnostics
o Other Diagnostics
o Research Studies
• Clinical Investigation
o Infectious Diseases
o Inherited Diseases
o Idiopathic Diseases
o Non-Communicable/Other Diseases
• Reproductive Health
o NIPT
o Aneuploidy
o Microdeletions
o PGT
o Newborn Genetic Screening
o Single Gene Analysis
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Sequencing
o Nucleic Acid Extraction
o Library Preparation
• Sequencing
• NGS Data Analysis
o NGS Primary Data Analysis
o NGS Secondary Data Analysis
o NGS Tertiary Data Analysis
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other users

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Technology
1.1.2. Product
1.1.3. Application
1.1.4. Workflow
1.1.5. End Use
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights
Chapter 3. Japan Next Generation Sequencing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising cancer burden & precision medicine initiatives
3.2.1.2. Supportive government policies & genomic programs
3.2.1.3. Rise in competition among prominent market entities
3.2.1.4. Rising clinical opportunity for NGS technology
3.2.2. Market restraint analysis
3.2.2.1. Lack of computational efficiency for data management
3.2.2.2. Non–value-based NGS reimbursement policy and regulation status
3.2.2.3. Challenges associated with NGS implementation.
3.3. Japan Next Generation Sequencing Market Analysis Tools
3.3.1. SWOT analysis; by factor (political & legal, economic, and technological)
3.3.2. Porter’s Five Forces Analysis
Chapter 4. Japan Next Generation Sequencing Market: Technology Business Analysis
4.1. Next Generation Sequencing Market: Technology Movement Analysis
4.2. Targeted Sequencing & Resequencing
4.2.1. Targeted Sequencing & Resequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
4.2.1.1. DNA-based targeted sequencing & resequencing
4.2.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
4.2.1.2. RNA-based targeted sequencing & resequencing
4.2.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
4.3. Whole Genome Sequencing
4.3.1. Whole Genome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
4.4. Whole Exome Sequencing
4.4.1. Whole Exome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
Chapter 5. Japan Next Generation Sequencing Market: Product Business Analysis
5.1. Next Generation Sequencing Market: Product Movement Analysis
5.2. Platforms
5.2.1. Platforms Market Estimates And Forecast, 2021 - 2033 (USD Million)
5.2.1.1. Sequencing
5.2.1.1.1. Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
5.2.1.2. Data Analysis
5.2.1.2.1. Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million
5.3. Consumables
5.3.1. Consumables market estimates and forecast, 2021 - 2033 (USD million)
5.3.2. Sample Preparation
5.3.2.1. Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
5.3.3. Target Enrichment
5.3.3.1. Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
5.3.4. Others
5.3.4.1. Others market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 6. Japan Next Generation Sequencing Market: Application Business Analysis
6.1. Next Generation Sequencing Market: Application Movement Analysis
6.2. Oncology
6.2.1. Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
6.2.2. Diagnostics & Screening
6.2.2.1. Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
6.2.2.2. Oncology screening
6.2.2.2.1. Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
6.2.2.2.2. Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
6.2.2.2.3. Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
6.2.2.3. Companion diagnostics
6.2.2.3.1. Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
6.2.2.4. Other diagnostics
6.2.2.4.1. Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
6.2.3. Research Studies
6.2.3.1. Research studies market estimates and forecast, 2021 - 2033 (USD Million)
6.3. Clinical investigation
6.3.1. Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
6.3.2. Infectious Diseases
6.3.2.1. Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
6.3.3. Idiopathic Diseases
6.3.3.1. Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
6.3.4. Inherited Diseases
6.3.4.1. Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
6.3.5. Non-Communicable/Other Diseases
6.3.5.1. Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
6.4. Reproductive Health
6.4.1. Reproductive Health Market Estimates And Forecast, 2021 - 2033 (USD Million)
6.4.2. NIPT
6.4.2.1. NIPT market estimates and forecast, 2021 - 2033 (USD Million)
6.4.2.2. Aneuploidy
6.4.2.2.1. Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
6.4.2.3. Microdeletions
6.4.2.3.1. Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
6.4.3. PGT
6.4.3.1. PGT market estimates and forecast, 2021 - 2033 (USD Million)
6.4.4. Newborn Genetic Screening
6.4.4.1. Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
6.4.5. Single Gene Analysis
6.4.5.1. Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
6.5. HLA Typing/Immune System Monitoring
6.5.1. HLA Typing/Immune System Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
6.6. Metagenomics, Epidemiology & Drug Development
6.6.1. Metagenomics, Epidemiology & Drug Development Market Estimates And Forecast, 2021 - 2033 (USD Million)
6.7. Agrigenomics & Forensics
6.7.1. Agrigenomics & Forensics Market Estimates And Forecast, 2021 - 2033 (USD Million)
6.8. Consumer Genomics
6.8.1. Consumer Genomics Market Estimates And Forecast, 2021 - 2033 (USD Million)
Chapter 7. Japan Next Generation Sequencing Market: Workflow Business Analysis
7.1. Next Generation Sequencing Market: Workflow Movement Analysis
7.2. Presequencing
7.2.1. Pre-Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
7.2.1.1. Nucleic Acid Extraction
7.2.1.1.1. Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
7.2.1.2. Library Preparation
7.2.1.2.1. Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
7.3. Sequencing
7.3.1. Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
7.4. Data Analysis
7.4.1. Data Analysis Market Estimates And Forecast, 2021 - 2033 (USD Million)
7.4.2. Primary Data NGS Analysis
7.4.2.1. Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
7.4.3. Secondary Data Analysis
7.4.3.1. Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
7.4.4. Tertiary Data Analysis
7.4.4.1. Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
Chapter 8. Japan Next Generation Sequencing Market: End Use Business Analysis
8.1. Next Generation Sequencing Market: End Use Movement Analysis
8.2. Academic Research
8.2.1. Academic Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
8.3. Clinical Research
8.3.1. Clinical Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
8.4. Hospitals & Clinics
8.4.1. Hospitals & Clinics Market Estimates And Forecast, 2021 - 2033 (USD Million)
8.5. Pharmaceutical & Biotech Entities
8.5.1. Pharmaceutical & Biotech Entities Market Estimates And Forecast, 2021 - 2033 (USD Million)
8.6. Other Users
8.6.1. Other Users Market Estimates And Forecast, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Key Company Market Position Analysis, 2024
9.4. Participants Overview
9.4.1. Illumina, Inc
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. QIAGEN
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Thermo Fisher Scientific, Inc
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. BGI
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Pacific Biosciences
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Bio Rad Laboratories
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Oxford Nanopore Technologies, Inc
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Myriad Genetics. Inc.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Agilent Technologies, Inc.
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Eurofins Scientific
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives